Bio-Path (BPTH) Competitors $0.14 0.00 (-1.79%) As of 08/14/2025 03:26 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. VIVS, INM, ADIL, TCRT, GLTO, INDP, CMND, DRMA, ALBT, and JAGXShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include VivoSim Labs (VIVS), InMed Pharmaceuticals (INM), Adial Pharmaceuticals (ADIL), Alaunos Therapeutics (TCRT), Galecto (GLTO), Indaptus Therapeutics (INDP), Clearmind Medicine (CMND), Dermata Therapeutics (DRMA), Avalon GloboCare (ALBT), and Jaguar Animal Health (JAGX). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors VivoSim Labs InMed Pharmaceuticals Adial Pharmaceuticals Alaunos Therapeutics Galecto Indaptus Therapeutics Clearmind Medicine Dermata Therapeutics Avalon GloboCare Jaguar Animal Health Bio-Path (NASDAQ:BPTH) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Do insiders and institutionals have more ownership in BPTH or VIVS? 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 3.7% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, BPTH or VIVS? VivoSim Labs has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/AVivoSim Labs$140K33.43-$2.48M-$10.20-0.18 Is BPTH or VIVS more profitable? Bio-Path has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,396.48%. VivoSim Labs' return on equity of -32.95% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% VivoSim Labs -1,396.48%-32.95%-21.31% Does the media favor BPTH or VIVS? In the previous week, VivoSim Labs had 5 more articles in the media than Bio-Path. MarketBeat recorded 7 mentions for VivoSim Labs and 2 mentions for Bio-Path. Bio-Path's average media sentiment score of 1.00 beat VivoSim Labs' score of 0.60 indicating that Bio-Path is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Path 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, BPTH or VIVS? Bio-Path has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. SummaryVivoSim Labs beats Bio-Path on 8 of the 10 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14M$791.77M$5.61B$9.84BDividend YieldN/A4.84%4.61%4.07%P/E RatioN/A1.1830.2825.74Price / SalesN/A26.06460.47115.79Price / CashN/A19.5638.2159.48Price / Book0.196.588.856.15Net Income-$16.08M-$4.98M$3.25B$265.06M7 Day Performance-1.79%1.86%3.72%2.60%1 Month Performance-15.59%0.45%5.86%2.83%1 Year Performance-90.77%16.14%30.34%25.58% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path1.7962 of 5 stars$0.14-1.8%N/A-90.9%$1.14MN/A0.0010News CoverageNegative NewsShort Interest ↓Gap UpVIVSVivoSim LabsN/A$1.90+2.7%N/AN/A$4.81M$140K-0.1920News CoverageEarnings ReportINMInMed Pharmaceuticals1.35 of 5 stars$2.37-0.8%N/A-21.1%$4.79M$4.60M-0.2010Short Interest ↓ADILAdial Pharmaceuticals2.5952 of 5 stars$0.42-8.7%$8.00+1,825.9%-59.1%$4.75MN/A-0.2820News CoverageEarnings ReportShort Interest ↑Gap DownTCRTAlaunos Therapeutics1.2371 of 5 stars$3.02+10.2%N/A-0.8%$4.49M$11K-1.1940Earnings ReportShort Interest ↓GLTOGalecto3.8067 of 5 stars$3.38+5.6%$10.00+195.9%-74.2%$4.24MN/A-0.2240Short Interest ↓Gap UpHigh Trading VolumeINDPIndaptus Therapeutics3.2399 of 5 stars$7.30flat$238.00+3,160.3%-83.4%$4.18MN/A-0.176News CoverageEarnings ReportGap DownCMNDClearmind Medicine1.0245 of 5 stars$0.98+1.0%N/A-8.9%$4.14MN/A-0.89N/AShort Interest ↓Gap UpDRMADermata Therapeutics3.1133 of 5 stars$7.06+9.5%$30.00+324.9%-74.3%$4.11MN/A-0.438Negative NewsEarnings ReportShort Interest ↓Gap UpHigh Trading VolumeALBTAvalon GloboCare1.1807 of 5 stars$2.26+4.6%N/A-69.5%$4.09M$1.37M-0.115Earnings ReportUpcoming EarningsShort Interest ↑JAGXJaguar Animal Health2.0145 of 5 stars$2.15+8.6%$60.00+2,690.7%-92.3%$3.79M$11.69M0.0050News CoverageNegative NewsEarnings Report Related Companies and Tools Related Companies VIVS Alternatives INM Alternatives ADIL Alternatives TCRT Alternatives GLTO Alternatives INDP Alternatives CMND Alternatives DRMA Alternatives ALBT Alternatives JAGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access